Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8586822 | 0.96 | CTSB (0.43) | CTSBSLC15A1ABCB1SLC1A3SLC1A2 | |
| SCHEMBL8586153 | 0.91 | CTSB (0.45) | CTSBSLC15A1ABCB1SLC1A3SLC1A2 | |
| SCHEMBL8584621 | 0.90 | CTSB (0.41) | CTSBSLC15A1ABCB1SLC1A3SLC1A2 | |
| SCHEMBL8586490 | 0.90 | SLC1A3 (0.43) | CTSBSLC15A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8585981 | 0.89 | SLC15A1 (0.43) | CTSBSLC15A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8587702 | 0.87 | CTSB (0.42) | CTSBSLC15A1ABCB1SLC1A3SLC1A2 | |
| SCHEMBL8583695 | 0.87 | SLC15A1 (0.45) | CTSBSLC15A1ABCB1SLC1A3SLC1A2 | |
| SCHEMBL8586223 | 0.87 | SLC1A3 (0.43) | CTSBSLC15A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8586811 | 0.86 | CTSB (0.47) | CTSBSLC15A1ABCB1LTA4H | |
| SCHEMBL8583680 | 0.86 | ACE (0.41) | CTSBSLC15A1ABCB1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | disclosed |
| US-20150352196-A1 | Methods and Pharmaceutical Compositions for Prevention of Aging-Related Lesions | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2015-12-10 | — | — | US | disclosed |
| EP-2934573-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF AGING-RELATED LESIONS | Assistance Publique-Hôpitaux de Paris (FR) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015032841-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OR TREATMENT OF TH17 MEDIATED DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-03-12 | — | — | WO | disclosed |
| WO-2014096087-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF AGING-RELATED LESIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-06-26 | — | — | WO | disclosed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110117106-A1 | USES OF CALPAIN INHIBITORS TO INHIBIT INFLAMMATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2011-05-19 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-7862811-B2 | Protease inhibition for prevention or treatment of heart failure | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-01-04 | — | — | US | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060234971-A1 | Calpains as targets for inhibition of prion propagation | UNIVERSITY OF KENTUCKY (US) | 2006-10-19 | — | — | US | disclosed |
| US-20050238633-A1 | Protease inhibition for prevention or treatment of heart failure | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2005-10-27 | — | — | US | disclosed |
| WO-2005004905-A1 | USE OF CALPAIN FOR IDENTIFYING COMPOUNDS THAT MODULATE PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
| US-20050014182-A1 | Use of calpain for identifying compounds that modulate pain | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20040229209-A1 | Model for Alzheimer's disease and other neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-11-18 | — | — | US | disclosed |
| US-6803233-B2 | Model for Alzheimer's disease and other neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
| WO-2002010768-A9 | MODEL FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2003-07-10 | — | — | WO | disclosed |
| US-20020048746-A1 | Model for alzheimer's disease and other neurodegenerative diseases | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CTSB 673/4885SLC15A1 3622/4885ABCB1 1824/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CTSB 673/4885SLC15A1 3622/4885ABCB1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.